The Myeloid Molecular Profile detects mutations in key genes recurrently mutated in myeloid malignancies. Genomic DNA is isolated from bone marrow aspirates or peripheral blood and the DNA sequence of targeted regions of the ASXL1, BCOR, BRAF, CALR, CBL, CEBPA, CSF3R, DDX41, DNMT3A, ETNK1, ETV6, EZH2, GATA2, GNAS, GNB1, IDH1, IDH2, JAK2, KIT, KRAS, MPL, NF1, NPM1, NRAS, PDGFRA, PHF6, PPM1D, PTPN11, RAD21, RUNX1, SETBP1, SF3B1, SH2B3, SMC1A, SMC3, SRSF2, STAG2, STAT3, STAT5B, TET2, TP53, U2AF1, WT1, ZRSR2 genes is determined using next-generation sequencing (NGS) technology.
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
ASXL1 (ASXL Transcriptional Regulator 1), BRAF (B-raf proto-oncogene), CBL (Cbl proto-oncogene), CEBPA (CCAAT Enhancer Binding Protein Alpha), CSF3R (Colony Stimulating Factor 3 Receptor), DNMT3A (DNA methyltransferase 1)
See More ...
Next-Generation Sequencing (NGS)